✦ LIBER ✦

Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma

✍ Scribed by Margulis, Vitaly; Matin, Surena F.; Tannir, Nizar; Tamboli, Pheroze; Swanson, David A.; Jonasch, Eric; Wood, Christopher G.

Book ID: 122504798
Publisher: Lippincott Williams and Wilkins
Year: 2008
Tongue: English
Weight: 72 KB
Volume: 180
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2008.03.047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Surgical Morbidity Associated with A

Re: Surgical Morbidity Associated with Administration of Targeted Molecular Therapies before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma

✍ Robert C. Flanigan; Anthony Pulcari 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Corrigendum to: “Re: Surgical Morbidity

Corrigendum to: “Re: Surgical Morbidity Associated with Administration of Targeted Molecular Therapies before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma” [Eur Urol 2009;55:990–1]

✍ Robert C. Flanigan; Anthony Polcari 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Surgical morbidity associated with admin

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma: Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG, Department of Urology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX

✍ Michael L. Blute 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 86 KB

SURGICAL MORBIDITY ASSOCIATED WITH ADMIN

SURGICAL MORBIDITY ASSOCIATED WITH ADMINISTRATION OF TARGETED MOLECULAR THERAPIES PRIOR TO CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA

✍ Margulis, Vitaly; Matin, Surena F; Tamboli, Pheroze; Swanson, David A; Wood, Chr 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 156 KB

POD-6.07: Surgical Morbidity Associated

POD-6.07: Surgical Morbidity Associated with Administration of Targeted Molecular Therapies Prior to Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

✍ C. Wood; V. Margulis; S. Matin; P. Tamboli; D. Swanson 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB